{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:23:09Z","timestamp":1792444989379,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several attempts have been made to enhance N-methyl-D-aspartate (NMDA) receptor function in schizophrenia, but they have yielded mixed results. Luvadaxistat, a D-amino acid oxidase (DAAO) inhibitor that increases the glutamate co-agonist D-serine levels, is being developed for the treatment of cognitive impairment associated with schizophrenia. We conducted a biomarker study in patients, assessing several endpoints related to physiological outcomes of NMDA receptor modulation to determine whether luvadaxistat affects neural circuitry biomarkers relevant to NMDA receptor function and schizophrenia. This was a randomized, placebo-controlled, double-blind, two-period crossover phase 2a study assessing luvadaxistat 50\u2009mg and 500\u2009mg for 8 days in 31 patients with schizophrenia. There were no treatment effects of luvadaxistat at either dose in eyeblink conditioning, a cerebellar-dependent learning measure, compared with placebo. We observed a nominally significant improvement in mismatch negativity (MMN) and a statistical trend to improvement for auditory steady-state response at 40\u2009Hz, in both cases with 50\u2009mg, but not with 500\u2009mg, compared with placebo. Although the data should be interpreted cautiously owing to the small sample size, they suggest that luvadaxistat can improve an illness-related circuitry biomarker at doses associated with partial DAAO inhibition. These results are consistent with 50\u2009mg, but not higher doses, showing a signal of efficacy in cognitive endpoints in a larger phase 2, 12-week study conducted in parallel. Thus, MMN responses after a short treatment period may predict cognitive function improvement. MMN and ASSR should be considered as biomarkers in early trials addressing NMDA receptor hypofunction.<\/jats:p>","DOI":"10.1038\/s41386-023-01560-0","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T19:55:44Z","timestamp":1679860544000},"page":"1052-1059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial"],"prefix":"10.1038","volume":"48","author":[{"given":"Patricio","family":"O\u2019Donnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesha","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Asgharnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7206-5282","authenticated-orcid":false,"given":"Xiaoming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Summerfelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens R.","family":"Wendland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Dunayevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek L.","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Litman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Hetrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Elliot","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"1560_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR. Recent advances in the phenciclidine model of schizophrenia. Am J Psychiat. 1991;148:1301\u20138.","journal-title":"Am J Psychiat"},{"key":"1560_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev.pharmtox.42.082701.160735","volume":"42","author":"G Tsai","year":"2002","unstructured":"Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002;42:165\u201379.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1560_CR3","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/0269881118822157","volume":"33","author":"CH Chang","year":"2019","unstructured":"Chang CH, Lane HY, Tseng PT, Chen SJ, Liu CY, Lin CH. Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. J Psychopharmacol. 2019;33:436\u201348.","journal-title":"J Psychopharmacol"},{"key":"1560_CR4","first-page":"445","volume":"22","author":"P O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell P, Rosen L, Alexander R, Murthy V, Davies CH, Ratti E. Strategies to Address Challenges in Neuroscience Drug Discovery and Development. Int J Neuropsychopharmacol. 2019;22:445\u20138.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1560_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1126\/science.2841759","volume":"241","author":"NW Kleckner","year":"1988","unstructured":"Kleckner NW, Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science. 1988;241:835\u20137.","journal-title":"Science."},{"key":"1560_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1001\/archpsyc.60.6.572","volume":"60","author":"K Hashimoto","year":"2003","unstructured":"Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003;60:572\u20136.","journal-title":"Arch Gen Psychiatry"},{"key":"1560_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.pnpbp.2005.04.023","volume":"29","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:767\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1560_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics C.","year":"2014","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421\u20137.","journal-title":"Nature."},{"key":"1560_CR9","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1176\/ajp.152.8.1213","volume":"152","author":"DC Goff","year":"1995","unstructured":"Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 1995;152:1213\u20135.","journal-title":"Am J Psychiatry"},{"key":"1560_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","volume":"56","author":"DC Goff","year":"1999","unstructured":"Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56:21\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"1560_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1176\/appi.ajp.159.3.480","volume":"159","author":"U Heresco-Levy","year":"2002","unstructured":"Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry. 2002;159:480\u20132.","journal-title":"Am J Psychiatry"},{"key":"1560_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00213-004-2032-2","volume":"179","author":"DC Goff","year":"2005","unstructured":"Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology. 2005;179:144\u201350.","journal-title":"Psychopharmacology"},{"key":"1560_CR13","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","volume":"164","author":"RW Buchanan","year":"2007","unstructured":"Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164:1593\u2013602.","journal-title":"Am J Psychiatry"},{"key":"1560_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.schres.2004.03.013","volume":"71","author":"EJ Duncan","year":"2004","unstructured":"Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, et al. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res. 2004;71:239\u201348.","journal-title":"Schizophr Res"},{"key":"1560_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2165\/11586650-000000000-00000","volume":"25","author":"SP Singh","year":"2011","unstructured":"Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011;25:859\u201385.","journal-title":"CNS Drugs"},{"key":"1560_CR16","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","volume":"44","author":"G Tsai","year":"1998","unstructured":"Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998;44:1081\u20139.","journal-title":"Biol Psychiatry"},{"key":"1560_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.biopsych.2004.12.037","volume":"57","author":"U Heresco-Levy","year":"2005","unstructured":"Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry. 2005;57:577\u201385.","journal-title":"Biol Psychiatry"},{"key":"1560_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.schres.2017.02.027","volume":"191","author":"JT Kantrowitz","year":"2018","unstructured":"Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, et al. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophr Res. 2018;191:70\u20139.","journal-title":"Schizophr Res"},{"key":"1560_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.schres.2010.05.012","volume":"121","author":"JT Kantrowitz","year":"2010","unstructured":"Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res. 2010;121:125\u201330.","journal-title":"Schizophr Res"},{"key":"1560_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/mp.2009.99","volume":"15","author":"L Verrall","year":"2010","unstructured":"Verrall L, Burnet PW, Betts JF, Harrison PJ. The neurobiology of D-amino acid oxidase and its involvement in schizophrenia. Mol Psychiatry. 2010;15:122\u201337.","journal-title":"Mol Psychiatry"},{"key":"1560_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-8-94","volume":"8","author":"I Benzel","year":"2008","unstructured":"Benzel I, Kew JN, Viknaraja R, Kelly F, de Belleroche J, Hirsch S, et al. Investigation of G72 (DAOA) expression in the human brain. BMC Psychiatry. 2008;8:94.","journal-title":"BMC Psychiatry"},{"key":"1560_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fnana.2017.00031","volume":"11","author":"V Jagannath","year":"2017","unstructured":"Jagannath V, Marinova Z, Monoranu CM, Walitza S, Grunblatt E. Expression of D-Amino Acid Oxidase (DAO\/DAAO) and D-Amino Acid Oxidase Activator (DAOA\/G72) during Development and Aging in the Human Post-mortem Brain. Front Neuroanat. 2017;11:31.","journal-title":"Front Neuroanat"},{"key":"1560_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.schres.2008.02.002","volume":"101","author":"C Madeira","year":"2008","unstructured":"Madeira C, Freitas ME, Vargas-Lopes C, Wolosker H, Panizzutti R. Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res. 2008;101:76\u201383.","journal-title":"Schizophr Res"},{"key":"1560_CR24","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1073\/pnas.97.9.4926","volume":"97","author":"JP Mothet","year":"2000","unstructured":"Mothet JP, Parent AT, Wolosker H, Brady RO Jr., Linden DJ, Ferris CD, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA. 2000;97:4926\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1560_CR25","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamapsychiatry.2013.2159","volume":"70","author":"HY Lane","year":"2013","unstructured":"Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 2013;70:1267\u201375.","journal-title":"JAMA Psychiatry"},{"key":"1560_CR26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/0006-3223(93)90005-X","volume":"33","author":"DC Javitt","year":"1993","unstructured":"Javitt DC, Doneshka P, Zylberman I, Ritter W, Vaughan HG Jr. Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study. Biol Psychiatry. 1993;33:513\u20139.","journal-title":"Biol Psychiatry"},{"key":"1560_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2004.12.002","volume":"76","author":"D Umbricht","year":"2005","unstructured":"Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res. 2005;76:1\u201323.","journal-title":"Schizophr Res"},{"key":"1560_CR28","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.biopsych.2006.03.055","volume":"60","author":"GA Light","year":"2006","unstructured":"Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, et al. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry. 2006;60:1231\u201340.","journal-title":"Biol Psychiatry"},{"key":"1560_CR29","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/archpsyc.57.12.1139","volume":"57","author":"D Umbricht","year":"2000","unstructured":"Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry. 2000;57:1139\u201347.","journal-title":"Arch Gen Psychiatry"},{"key":"1560_CR30","doi-asserted-by":"publisher","first-page":"pyu118","DOI":"10.1093\/ijnp\/pyu118","volume":"18","author":"EM Sullivan","year":"2015","unstructured":"Sullivan EM, Timi P, Hong LE, O\u2019Donnell P. Effects of NMDA and GABA-A Receptor Antagonism on Auditory Steady-State Synchronization in Awake Behaving Rats. Int J Neuropsychopharmacol. 2015;18:pyu118.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1560_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02096-5","volume":"12","author":"C Schultheis","year":"2022","unstructured":"Schultheis C, Rosenbrock H, Mack SR, Vinisko R, Schuelert N, Plano A, et al. Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: A Phase II substudy of patients treated with iclepertin (BI 425809). Transl Psychiatry. 2022;12:329.","journal-title":"Transl Psychiatry"},{"key":"1560_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0006-8993(01)02532-X","volume":"905","author":"RF Rogers","year":"2001","unstructured":"Rogers RF, Britton GB, Steinmetz JE. Learning-related interpositus activity is conserved across species as studied during eyeblink conditioning in the rat. Brain Res. 2001;905:171\u20137.","journal-title":"Brain Res"},{"key":"1560_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.schres.2009.03.016","volume":"111","author":"AR Bolbecker","year":"2009","unstructured":"Bolbecker AR, Mehta CS, Edwards CR, Steinmetz JE, O\u2019Donnell BF, Hetrick WP. Eye-blink conditioning deficits indicate temporal processing abnormalities in schizophrenia. Schizophr Res. 2009;111:182\u201391.","journal-title":"Schizophr Res"},{"key":"1560_CR34","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.2008.08040597","volume":"166","author":"AR Bolbecker","year":"2009","unstructured":"Bolbecker AR, Hetrick WP, Johannesen JK, O\u2019Donnell BF, Steinmetz JE, Shekhar AS. Secretin effects on cerebellar-dependent motor learning in schizophrenia. Am J Psychiatry. 2009;166:460\u20136.","journal-title":"Am J Psychiatry"},{"key":"1560_CR35","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/S1388-2457(00)00377-1","volume":"111","author":"DC Javitt","year":"2000","unstructured":"Javitt DC, Shelley A, Ritter W. Associated deficits in mismatch negativity generation and tone matching in schizophrenia. Clin Neurophysiol. 2000;111:1733\u20137.","journal-title":"Clin Neurophysiol"},{"key":"1560_CR36","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.biopsych.2005.08.030","volume":"59","author":"DS Umbricht","year":"2006","unstructured":"Umbricht DS, Bates JA, Lieberman JA, Kane JM, Javitt DC. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol Psychiatry. 2006;59:762\u201372.","journal-title":"Biol Psychiatry"},{"key":"1560_CR37","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/jamapsychiatry.2015.2680","volume":"73","author":"LM Rowland","year":"2016","unstructured":"Rowland LM, Summerfelt A, Wijtenburg SA, Du X, Chiappelli JJ, Krishna N, et al. Frontal Glutamate and gamma-Aminobutyric Acid Levels and Their Associations With Mismatch Negativity and Digit Sequencing Task Performance in Schizophrenia. JAMA Psychiatry. 2016;73:166\u201374.","journal-title":"JAMA Psychiatry"},{"key":"1560_CR38","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/npp.2009.168","volume":"35","author":"LE Hong","year":"2010","unstructured":"Hong LE, Summerfelt A, Buchanan RW, O\u2019Donnell P, Thaker GK, Weiler MA, et al. Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology. 2010;35:632\u201340.","journal-title":"Neuropsychopharmacology."},{"key":"1560_CR39","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/schbul\/sbx078","volume":"44","author":"KC Puvvada","year":"2018","unstructured":"Puvvada KC, Summerfelt A, Du X, Krishna N, Kochunov P, Rowland LM, et al. Delta Vs Gamma Auditory Steady State Synchrony in Schizophrenia. Schizophr Bull. 2018;44:378\u201387.","journal-title":"Schizophr Bull"},{"key":"1560_CR40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","volume":"68","author":"RS Keefe","year":"2004","unstructured":"Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68:283\u201397.","journal-title":"Schizophr Res"},{"key":"1560_CR41","unstructured":"Murthy V, Hanson E, DeMartinis N, Asgharnejad M, Dong C, Evans R, et al. Luvadaxistat, an investigational D-amino acid oxidase inhibitor, was associated with signals of efficacy in cognitive impairment associated with schizophrenia but not negative symptoms: Results from the interact study. Neuropsychopharmacology. 2021;46:374\u20135."},{"key":"1560_CR42","unstructured":"Serrats J, Fradley R, Murthy V, O\u2019Donnell P, Asgharnejad M. Pre-clinical evaluation of hippocampal long-term potentiation after acute and sub-chronic oral dosing with luvadaxistat in mice. Neuropsychopharmacology. 2021;46:322\u20133."},{"key":"1560_CR43","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1515\/revneuro-2015-0066","volume":"27","author":"A Rubio-Casillas","year":"2016","unstructured":"Rubio-Casillas A, Fernandez-Guasti A. The dose makes the poison: from glutamate-mediated neurogenesis to neuronal atrophy and depression. Rev Neurosci. 2016;27:599\u2013622.","journal-title":"Rev Neurosci"},{"key":"1560_CR44","doi-asserted-by":"crossref","unstructured":"Sehatpour P, Iosifescu DV, De Baun HM, Shope C, Mayer MR, Gangswich J, et al. Dose dependent augmentation of neuroplasticity-based auditory learning in schizophrenia: a double-blind, placebo-controlled, randomized, target engagement clinical trial of the N-methyl-D-aspartate-type glutamate receptor (NMDAR) agonist d-serine. Biol Psychiatry. 2023. In press.","DOI":"10.1016\/j.biopsych.2023.01.015"},{"key":"1560_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s12311-008-0060-x","volume":"7","author":"M Molinari","year":"2008","unstructured":"Molinari M, Chiricozzi FR, Clausi S, Tedesco AM, De Lisa M, Leggio MG. Cerebellum and detection of sequences, from perception to cognition. Cerebellum. 2008;7:611\u20135.","journal-title":"Cerebellum."},{"key":"1560_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/oxfordjournals.schbul.a033321","volume":"24","author":"NC Andreasen","year":"1998","unstructured":"Andreasen NC, Paradiso S, O\u2019Leary DS. \u201cCognitive dysmetria\u201d as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry? Schiz Bull. 1998;24:203\u201318.","journal-title":"Schiz Bull"},{"key":"1560_CR47","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1017\/S003329171800003X","volume":"48","author":"J Ferri","year":"2018","unstructured":"Ferri J, Ford JM, Roach BJ, Turner JA, van Erp TG, Voyvodic J, et al. Resting-state thalamic dysconnectivity in schizophrenia and relationships with symptoms. Psychol Med. 2018;48:2492\u201399.","journal-title":"Psychol Med"},{"key":"1560_CR48","doi-asserted-by":"publisher","first-page":"e0223127","DOI":"10.1371\/journal.pone.0223127","volume":"14","author":"V Parciauskaite","year":"2019","unstructured":"Parciauskaite V, Voicikas A, Jurkuvenas V, Tarailis P, Kraulaidis M, Pipinis E, et al. 40-Hz auditory steady-state responses and the complex information processing: An exploratory study in healthy young males. PLoS ONE. 2019;14:e0223127.","journal-title":"PLoS ONE"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01560-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01560-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01560-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T14:03:22Z","timestamp":1684937002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01560-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1560"],"URL":"https:\/\/doi.org\/10.1038\/s41386-023-01560-0","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"assertion":[{"value":"14 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"POD and DLB were employed at Takeda Pharmaceuticals USA, Inc. throughout the conception and execution of the study and are currently employees and shareholders of Sage Therapeutics. CD, VM, MA, HL, LX, JRW, and LBR are employees of Takeda Pharmaceuticals USA, Inc., and shareholders of Takeda Pharmaceutical Company Limited. ED is an employee of Neurocrine Biosciences Inc. and was employed at Takeda when the study was initiated. LEH has received or plans to receive research funding or consulting fees from Heptares Therapuetics Ltd, Luye Pharma Group, Mitsubishi, Neuralstem Inc., Pfizer, Regeneron, Sound Pharma, Taisho Pharmaceutical, Takeda, and Your Energy Systems LLC. XD, AS, RL, and WPH have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}